DE3641220A1 - Pharmaceutical compositions for treatment of psoriasis or neurodermatitis - Google Patents
Pharmaceutical compositions for treatment of psoriasis or neurodermatitisInfo
- Publication number
- DE3641220A1 DE3641220A1 DE19863641220 DE3641220A DE3641220A1 DE 3641220 A1 DE3641220 A1 DE 3641220A1 DE 19863641220 DE19863641220 DE 19863641220 DE 3641220 A DE3641220 A DE 3641220A DE 3641220 A1 DE3641220 A1 DE 3641220A1
- Authority
- DE
- Germany
- Prior art keywords
- extracts
- psoriasis
- neurodermatitis
- echinacea
- gelsemium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 14
- 238000011282 treatment Methods 0.000 title claims abstract description 13
- 201000009053 Neurodermatitis Diseases 0.000 title claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 14
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims abstract description 14
- 238000010790 dilution Methods 0.000 claims abstract description 13
- 239000012895 dilution Substances 0.000 claims abstract description 13
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 9
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 7
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 7
- 229960002104 cyanocobalamin Drugs 0.000 claims abstract description 7
- 235000000639 cyanocobalamin Nutrition 0.000 claims abstract description 7
- 239000011666 cyanocobalamin Substances 0.000 claims abstract description 7
- 229960000520 diphenhydramine Drugs 0.000 claims abstract description 7
- 235000014134 echinacea Nutrition 0.000 claims abstract description 7
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229960004919 procaine Drugs 0.000 claims abstract description 7
- 244000133098 Echinacea angustifolia Species 0.000 claims abstract description 6
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims abstract description 5
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims abstract description 5
- 230000001632 homeopathic effect Effects 0.000 claims abstract description 5
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims abstract description 5
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000005493 rutin Nutrition 0.000 claims abstract description 5
- 229960004555 rutoside Drugs 0.000 claims abstract description 5
- 241000735527 Eupatorium Species 0.000 claims abstract description 4
- 241000271496 Lachesis Species 0.000 claims abstract description 4
- 239000011734 sodium Substances 0.000 claims abstract description 4
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 4
- 241001113926 Gelsemium Species 0.000 claims abstract description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract 2
- 239000012675 alcoholic extract Substances 0.000 claims abstract 2
- 229940083542 sodium Drugs 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 9
- 241000723370 Cocculus Species 0.000 claims description 5
- 241000723377 Coffea Species 0.000 claims description 5
- 241000723368 Conium Species 0.000 claims description 5
- 241001516485 Cypripedium Species 0.000 claims description 5
- 235000016787 Piper methysticum Nutrition 0.000 claims description 5
- 240000005546 Piper methysticum Species 0.000 claims description 5
- VJKUPQSHOVKBCO-RYVYVXLVSA-N cocculus solid Chemical compound O([C@@H]1C[C@]2(O)[C@@]34C)C14C(=O)O[C@@H]3[C@@H]1[C@H](C(=C)C)[C@H]2C(=O)O1.O([C@@H]1C[C@]2(O)[C@@]34C)C14C(=O)O[C@@H]3[C@@H]1[C@H](C(C)(O)C)[C@H]2C(=O)O1 VJKUPQSHOVKBCO-RYVYVXLVSA-N 0.000 claims description 5
- 241000206501 Actaea <angiosperm> Species 0.000 claims description 4
- 241001473306 Eupatorium perfoliatum Species 0.000 claims description 4
- 241001136643 Gelsemium sempervirens Species 0.000 claims description 4
- 235000017309 Hypericum perforatum Nutrition 0.000 claims description 4
- 241000218996 Passiflora Species 0.000 claims description 4
- 235000020694 echinacea extract Nutrition 0.000 claims description 4
- -1 sodium rutin sulfuric acid ester Chemical class 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 241000546188 Hypericum Species 0.000 claims description 3
- 241000792914 Valeriana Species 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 229940098465 tincture Drugs 0.000 claims description 3
- 235000017468 valeriana Nutrition 0.000 claims description 3
- 240000004530 Echinacea purpurea Species 0.000 claims description 2
- 239000006286 aqueous extract Substances 0.000 claims description 2
- XFXKRQZMTKNFHT-ZAAWVBGYSA-N 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxychromen-4-one;sulfuric acid Chemical compound OS(O)(=O)=O.O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 XFXKRQZMTKNFHT-ZAAWVBGYSA-N 0.000 claims 1
- 239000000419 plant extract Substances 0.000 abstract description 4
- 229960003966 nicotinamide Drugs 0.000 abstract description 3
- 235000005152 nicotinamide Nutrition 0.000 abstract description 3
- 239000011570 nicotinamide Substances 0.000 abstract description 3
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 abstract description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 229910021653 sulphate ion Inorganic materials 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 208000003251 Pruritus Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000007803 itching Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000271480 Lachesis muta Species 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 235000021192 high fiber diet Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 241000906543 Actaea racemosa Species 0.000 description 1
- 240000006450 Anamirta cocculus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 235000007460 Coffea arabica Nutrition 0.000 description 1
- 241000723367 Conium maculatum Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 244000051696 Jasminum odoratissimum Species 0.000 description 1
- 235000010257 Jasminum odoratissimum Nutrition 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 244000179684 Passiflora quadrangularis Species 0.000 description 1
- 235000011266 Passiflora quadrangularis Nutrition 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 241001113787 Strychnos Species 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 241000218215 Urticaceae Species 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 241000271897 Viperidae Species 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Chemical compound C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003555 analeptic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229930005303 indole alkaloid Natural products 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Die Erfindung betrifft Arzneimittel zur Behandlung der Psoriasis oder von Neurodermatitiden.The invention relates to medicaments for treatment psoriasis or neurodermatitis.
Bei der Psoriasis handelt es sich um eine nicht infektiöse, erblich disponierte und zu Rezidiven neigende System krankheit mit Entzündung und mit reversibler Be schleunigung des epidermalen Ceratinozytenumsatzes. Klinisch tritt die Psoriasis in Form scharfbegrenzter erythematöser, mit Schuppen bedeckter Herde verschiedener Größe und Gestalt auf, die häufig mit Juckreiz ver bunden sind. Die Psoriasis gehört zu den häufigsten Hauterkrankungen, der Anteil in der Bevölkerung wird auf etwa 5% geschätzt. Sie tritt bei beiden Geschlechtern etwa gleich häufig auf und kann in jedem Lebensalter mit einer Häufung der Erkrankung in der Jugend und während des Klimakteriums vorkommen. In etwa 3-5% aller Fälle ist die Psoriasis mit einer Polyarthritis assoziiert.Psoriasis is a non-infectious, Hereditary predisposed and recurring system disease with inflammation and with reversible loading acceleration of epidermal ceratinocyte turnover. Clinically, psoriasis occurs in the form of sharply defined erythematous, scaly-covered herd of different Size and shape that often ver itch are bound. Psoriasis is one of the most common Skin diseases, the proportion in the population estimated at about 5%. It occurs in both sexes about the same frequency and can be at any age with an accumulation of the disease in adolescence and occur during the menopause. In about 3-5% in all cases is psoriasis with polyarthritis associated.
Auch die Neurodermatitis, die gelegentlich auch als konstitutionelles Ektzem bezeichnet wird, ist eine erblich prädisponierte Erkrankung, deren Beginn meist in früher Kindheit mit Juckreiz, Rötung, Schuppen, Nesseln und Krustenbildung vorzugsweise am Gesicht und am behaarten Kopf beginnt. Auch die Erwachsenen-Neuro dermatitis äußert sich bevorzugt am Gesicht, Hals und Also neurodermatitis, which is sometimes called Constitutional ectzema is one hereditary predisposed disease, its onset mostly in early childhood with itching, redness, dandruff, Nettles and crust formation preferably on the face and starts on the hairy head. The adult neuros too dermatitis manifests itself preferentially on the face, neck and
Nacken und den Gelenkbeugen. Die Krankheit ist fast regelmäßig von quälendem Juckreiz begleitet, der ins besondere nachts auftritt und zu sogenannten Juck krisen führen kann. Mit zunehmendem Alter nimmt die Neurodermatitis meist an Intensität ab und verschwindet häufig um das sechzigste Lebensjahr.Neck and the flexors of the joints. The disease is almost regularly accompanied by excruciating itching, which ins special occurs at night and causes so-called itch can lead to crises. It increases with age Neurodermatitis mostly decreases in intensity and disappears often around the age of sixty.
Es ist bis heute bei beiden Erkrankungen nicht bekannt, welche Auslösermechanismen das Erscheinungsbild be dingen, obgleich im allgemeinen angenommen wird, daß die Krankheiten auf einem Zusammenwirken verschiedener Erbfaktoren und individuell sehr verschiedener endogener oder exogener Auslöserfaktoren beruhen. Seit einiger Zeit wird auch die Vermutung geäußert, daß beide Krankheiten zu den Autoimmunkrankheiten zu rechnen sind.It is still unknown in both diseases what trigger mechanisms the appearance things, although it is generally believed that the diseases on an interaction of different Hereditary factors and individually very different endogenous or exogenous trigger factors. For some Time is also suggested that both Diseases to be counted among the autoimmune diseases are.
Die bisherigen Behandlungsmethoden bestehen in der äußerlichen Anwendung verschiedener Arzneistoffe wie beispielsweise Teerderivate, Salicylsäure, Retinoide und insbesondere Corticosteroide sowie gegebenenfalls in der systemischen Therapie ebenfalls mit Retinoiden und wiederum überwiegend Corticosteroiden. Hinzukommt eine Beeinflussung durch Umweltfaktoren wie beispiels weise bei der Helio- oder Thalassotherapie sowie durch die Phototherapie mit UV-Licht, diese gegebenenfalls auch in Kombination mit systemischer Gabe von Retinoiden. Es hat sich jedoch herausgestellt, daß alle diese Therapiemaßnahmen nicht sicher und nur zeitlich be grenzt zu einem Verschwinden oder Schwächerwerden der klinischen Symptome führen und außerdem hat sich heraus gestellt, daß viele Erkrankungen bei Rezidiven nicht mehr auf die Therapie ansprechen, die bei einem vor hergehenden Schub noch zu einer Symptomfreiheit oder Linderung führte. Im übrigen sind die bisher üblichen Therapien mit beträchtlichen Nebenwirkungen behaftet, die nicht nur in geringerem Maße bei den Retinoiden, sondern regelmäßig bei der Gabe von Corticosteroiden auftreten und die zum Teil so schwerwiegend sein können, so daß sie zum Abbruch der Therapie nötigen.The previous treatment methods consist of external use of various drugs such as for example tar derivatives, salicylic acid, retinoids and in particular corticosteroids and, if appropriate in systemic therapy also with retinoids and again mostly corticosteroids. Come in addition an influence by environmental factors such as wise with helio or thalassotherapy and through phototherapy with UV light, if necessary also in combination with systemic administration of retinoids. However, it has been found that all of these Therapy measures are not certain and can only be timed limits the disappearance or weakening of the clinical symptoms and has also turned out posed that many diseases in relapses are not respond more to therapy than before thrust still leading to freedom from symptoms or Relief. Otherwise, they are the usual ones Therapies with considerable side effects, not only to a lesser extent with the retinoids, but regularly when taking corticosteroids occur and which are sometimes so serious can, so that they necessitate the termination of therapy.
Es besteht daher ein Bedürfnis, weitere Medikamente zur Behandlung der Psoriasis bzw. der Neurodermatitis zu entwickeln.There is therefore a need for more medication for the treatment of psoriasis or neurodermatitis to develop.
Zur Lösung der Aufgabe werden Arzneimittel zur Be handlung der Psoriasis oder der Neurodermatitis vor geschlagen, die dadurch gekennzeichnet sind, daß sie Diphenhydramin, Procain, Natriumsalze des Rutinschwefel säureesters, Cyanocobalamin, Ascorbinsäure, Nicotin amid sowie alkoholisch wässrige Auszüge aus Echinacea purpurea oder angustifolia, Eupatorium perfoliatum, Gelsemium sempervirens und Lachesis muta enthalten.To solve the problem, drugs are used treatment of psoriasis or neurodermatitis struck, which are characterized in that they Diphenhydramine, procaine, sodium salts of rutin sulfur acid esters, cyanocobalamin, ascorbic acid, nicotine amide and alcoholic aqueous extracts from Echinacea purpurea or angustifolia, Eupatorium perfoliatum, Contain Gelsemium sempervirens and Lachesis muta.
Bei der Behandlung der Neurodermatitis hat es sich als besonders günstig erwiesen, wenn das Arzneimittel zusätzlich noch zu den homoeopathischen Verdünnungen zwischen Urtinktur bis D12 enthält Ambra, Cocculus, Coffea, Conium, Cypripedium, Nux voumica, Passiflora, Valeriana, Hypericum, Kava Kava und Cimicifuga. In the treatment of neurodermatitis, it has proven to be particularly beneficial when the drug in addition to the homeopathic dilutions between mother tincture to D12 contains amber, Cocculus, Coffea, Conium, Cypripedium, Nux voumica, Passiflora, Valeriana, Hypericum, Kava Kava and Cimicifuga.
Bei Diphenhydramin handelt es sich um das Antihyster minikum N,N-Dimethyl-2-(diphenylmethoxy)-ethylamin, das neben den Antihystermineigenschaften auch einen ausgeprägten sedativen Effekt aufweist. Procain ist an und für sich ein bekanntes Lokalanästhetikum, das aber auch über regenerative Eigenschaften verfügt und das daher bereits seit langem zur Behandlung von Alters- und Abnutzungserscheingungen eingesetzt wird.Diphenhydramine is the antihyster minical N, N-dimethyl-2- (diphenylmethoxy) ethylamine, in addition to the antihystermine properties, also one has a pronounced sedative effect. Procaine is in itself a well-known local anesthetic, the but also has regenerative properties and therefore for a long time for the treatment of Age and wear conditions are used.
Rutin ist ein gefäßabdichtendes Mittel, dessen Wasser löslichkeit durch die Umwandlung in das Natriumsalz des entsprechenden Schwefelsäureesters stark erhöht und dessen Resorption damit verbessert wird.Rutin is a vascular sealing agent whose water solubility due to conversion to the sodium salt of the corresponding sulfuric acid ester greatly increased and its absorption is thus improved.
Ascorbinsäure, Cyanocobalamin und Nicotinamid sind Vitamine bzw. vitaminähnliche Verbindungen, die im Organismus, wie bekannt, in vielfältigen Reaktionen in den biochemischen Ablauf eingreifen.Ascorbic acid, cyanocobalamin and nicotinamide are Vitamins or vitamin-like compounds that in Organism, as is known, in diverse reactions intervene in the biochemical process.
Es ist bekannt, daß aus Echinacea-Arten wie angustifolia oder purpurea extrahierbare Wirkstoffauszüge Substanzen enhalten, die entzündungshemmend und abwehrsteigernd wirken; diese Wirkungen werden heute meist dem Echinaceacosid, einem Depsid mit bekannter Struktur, zugeschrieben. Echinaceaextrakte werden daher seit langem bei subakuten und chronischen entzündlichen Erkrankungen oder zur Unterstützung der Abwehr bei bakteriellen und Virus infektionen eingesetzt. Echinaceaextrakte sind auch bereits zur Behandlung der Psoriasis vorgeschlagen worden. It is known that from Echinacea species such as angustifolia or purpurea extractable drug extracts substances contain the anti-inflammatory and defense enhancing Act; these effects are mostly the Echinaceacosid, a Depsid with known structure, attributed to. Echinacea extracts have long been used in subacute and chronic inflammatory diseases or Defense against bacterial and virus infections used. Echinacea extracts are too already suggested for the treatment of psoriasis been.
Bei Gelsemium sempervirens handelt es sich um den aus Nordamerika stammenden gelben Jasmin, der unter anderem das giftige Indolalkaloid Gelsimin enthält. Gelsimin wirkt ZNS-stimmulierend und wird beispielsweise bei Keuchhusten eingesetzt. Auch Eupatorium perfoliatum enthält bei Extraktionen mit alkoholisch wässrigen Lösungsmitteln verschiedene Bestandteile, denen abwehrsteigernde und die Immunlage verbessernde Eigen schaften zugeschrieben werden. Bei Lachesis muta handelt es sich um die unter dem Namen Buschmeister bekannte und in ganz Süd- und Mittelamerika verbreitete Viper, deren Gift bereits seit langem in Zuge von Therapien auf Basis von Schlangengiften Verwendung findet. Schlangen gifte wie auch das der Lachesis muta sind sehr kompliziert zusammengesetzte Gemische, von denen bestimmte Teil fraktionen medizinisch beispielsweise zur allgemeinen Umstimmung und Besserung der Immunlage benutzt werden.Gelsemium sempervirens is the off North American yellow jasmine, among others contains the toxic indole alkaloid gelsimin. Gelsimin has a CNS-stimulating effect and is used, for example Whooping cough used. Also Eupatorium perfoliatum contains for extractions with alcoholic aqueous Solvents different ingredients, which defense-enhancing and immune-enhancing properties be attributed to companies. Lachesis muta it is known as the Buschmeister and viper widespread throughout South and Central America, their poison has long been in the course of therapies based on snake venoms. Snakes poisons like that of the Lachesis muta are very complicated compound mixtures, of which certain part Medical fractions, for example, for general purposes Reconsideration and improvement of the immune system can be used.
Die Dosierung von Diphenhydramin und Procain beträgt in der Regel 20 mg, diejenige des Rutinschwefelsäure esters ebenfalls 20 mg, während Cyanocobalamin in Mengen von etwa 3 mg, Nicotinamid in Mengen von 20 mg und Ascorbinsäure entsprechend etwa 40 mg gegeben werden. Der Echinaceaextrakt wird als Urtinktur bzw. in der Verdünnung D 1 in der Größenordnung von 400 mg, die Extrakte aus Eupatorium und Gelsemium in der Ver dünnung D 3 in Mengen von etwa 200 mg und Lachesis in der Verdünnung D 10 in Mengen von etwa 300 mg gegeben. The dosage of diphenhydramine and procain is usually 20 mg, that of rutinic sulfuric acid ester is also 20 mg, while cyanocobalamin is given in amounts of about 3 mg, nicotinamide in amounts of 20 mg and ascorbic acid correspondingly about 40 mg. The Echinacea extract is used as a mother tincture or in the dilution D 1 in the order of 400 mg, the extracts from Eupatorium and Gelsemium in the dilution D 3 in quantities of approximately 200 mg and Lachesis in the dilution D 10 in quantities of approximately 300 mg given.
Die Verabreichung des erfindungsgemäßen Mittels kann in flüssiger Form als Tropfen, in fester Form als Tabletten oder Dragees oder auch als Injektion er folgen. Die Herstellung der Zubereitungsform er folgt in an sich bekannter Weise.The administration of the agent according to the invention can in liquid form as drops, in solid form as Tablets or dragees or as an injection consequences. The preparation of the preparation form follows in a manner known per se.
Es hat sich herausgestellt, daß bei Psoriasisformen und insbesondere Neurodermatitiden, die mit starkem Juckreiz verbunden sind, ein Zusatz von verschiedenen Pflanzenextrakten in homoeopathischer Dosierung be sonders gute Ergebnisse erbringt. In bevorzugten Ausführungsformen enthalten die Medikamente daher zusätzlich Ambra, Cocculus, Coffea, Conium, Cypripedium und Nux voumica in Verdünnungen zwischen etwa D2 bis D12 im Falle von Conium. Bei Ambra handelt es sich um Walrat; Cocculus stammt aus der Pflanze Anamirta cocculus und das darin enthaltene Pikrotoxin wird medizinisch als Analepticum eingesetzt. Die Stammpflanze für Coffea ist Coffea arabica, deren Hauptinhaltsstoff Coffein ist. In der Homoeopathie wird Conium maculatum in großen Verdünnungen ebenso wie das aus Cypripedium resutum stammende Substanzgemisch und der Extrakt aus Strychnos nux voumica wegen seines Gehaltes an Strychnin als Beruhigungsmittel eingesetzt. Diesen Zubereitungen wird eine gewisse zentral beruhigende Eigenschaft nachgesagt.It has been found that in psoriasis forms and especially neurodermatitis associated with severe Itching associated with an addition of various Plant extracts in homeopathic dosage produces particularly good results. In preferred Embodiments therefore include the drugs additionally amber, cocculus, coffea, conium, cypripedium and Nux voumica in dilutions between about D2 to D12 in the case of conium. Ambra is about Spermaceti; Cocculus comes from the Anamirta cocculus plant and the picrotoxin it contains becomes medical used as an analeptic. The parent plant for Coffea is Coffea arabica, its main ingredient Is caffeine. In homeopathy, Conium maculatum in large dilutions as well as that from Cypripedium resutum originating mixture of substances and the extract Strychnos nux voumica because of its strychnine content used as a sedative. These preparations becomes a certain central calming property said.
Zusätzlich können die Arzneimittel auch noch homoeopathische Zubereitungen aus Passiflora-Arten, insbesondere Passiflora quadrangularis, aus Valeriana officinalis, Hypericum perforatum und Piper methysticum, auch genannt Kava Kava, enthalten. Diese Pflanzenextrakte werden ebenfalls in Verdünnungen zwischen etwa D2-D6 be nutzt. Die Extrakte gelten als wirksame Sedativa. Außerdem wird zusätzlich noch Cimicifuga aus der Stammpflanze Cimicifuga racemosa benutzt, deren Inhaltsstoffe als spasmolytisch und antirheumatisch angesehen werden.In addition, the drugs can also be homeopathic Preparations from Passiflora species, in particular Passiflora quadrangularis, from Valeriana officinalis, Hypericum perforatum and Piper methysticum, also called Kava Kava, included. These plant extracts are also in dilutions between about D2-D6 uses. The extracts are considered effective sedatives. In addition, Cimicifuga from the Root plant Cimicifuga racemosa used, their Ingredients as spasmolytic and anti-rheumatic be considered.
Die Dosierung der Pflanzenextrakte beträgt etwa 0,1 ml täglich in der angegebenen Verdünnung.The dosage of the plant extracts is approximately 0.1 ml daily in the specified dilution.
Überraschenderweise hat sich herausgestellt, daß die erfindungsgemäßen Arzneimittel auch bei langjährigen und schweren Fällen von Psoriasis und Neurodermatitis hervorragend wirksam sind und zu einer völligen Abheilung aller Hauterscheinungen führen. Bereits nach 4-6 Wochen sind in der Regel die Erytheme vollständig abge heilt, aber die Therapie kann, da praktisch nebenwirkungs frei, über längere Zeit durchgeführt werden. Vorzugs weise wird die Therapie durch eine säurearme, aber ballaststoffreiche Diät unterstützt. In schwierigen Fällen hat es sich auch als nützlich erwiesen, daß er findungsgemäße Arzneimittel als Injektion zusammen mit jeweils etwa 4-5 ml Eigenblut zu verabreichen.Surprisingly, it has been found that the pharmaceuticals according to the invention even in long-term and severe cases of psoriasis and neurodermatitis are extremely effective and lead to complete healing of all skin symptoms. Already after 4-6 Weeks are usually completely erythema heals, but therapy can be practical as a side effect free to be carried out over a long period of time. Preferential The therapy is wise by a low acidity, however Supports high fiber diet. In difficult In cases, it has also proven useful that he Medicines according to the invention as an injection together with Give approximately 4-5 ml of your own blood.
Die Erfindung wird im folgenden anhand der Beispiele näher erläutert:The invention is illustrated below with the aid of the examples explained in more detail:
Berechnet auf Basis einer Ampulle wird aus 40 mg Ascorbinsäure, 3 mg Cyanocobalamin, 20 mg Diphenhydramin HCl, 20 mg Procain HCl, 20 mg Natrium-Rutinschwefelsäureester, 20 mg Nicotinamid, 400 mg Echinacea D 1, je 200 mg Gelsemium sempervirens und Eupatorium perfoliatum D3 und 300 mg Lachesis muta D10 sowie 2 ml Wasser eine Lösung hergestellt und in üblicher Weise zu Injektionslösungen verarbeitet.Calculated on the basis of an ampoule, 40 mg ascorbic acid, 3 mg cyanocobalamin, 20 mg diphenhydramine HCl, 20 mg procaine HCl, 20 mg sodium rutin sulfuric acid ester, 20 mg nicotinamide, 400 mg Echinacea D 1 , 200 mg Gelsemium sempervirens and Eupatorium perfoliatum D3 and 300 mg of Lachesis muta D10 and 2 ml of water are prepared and processed in the usual way to give solutions for injection.
Es werden in üblicher Weise Injektionslösungen hergestellt, bei denen pro Ampulle die Mischung des Beispiels 1 zu sätzlich je 0,1 ml Ambra D 12, Cocculus D 4, Cimicifuga D 2, Coffea D 2, Conium D 4, Cypripedium D 3, Hypericum D 2, Kava Kava D 2, Nux voumica D4, Passiflora D 4 und Valeriana D 2 enthält.Injection solutions are prepared in the usual way, in which the mixture of Example 1 is additionally added to each 0.1 ml of Ambra D 12 , Cocculus D 4 , Cimicifuga D 2 , Coffea D 2 , Conium D 4 , Cypripedium D 3 , Hypericum D 2 , Kava Kava D 2 , Nux voumica D4, Passiflora D 4 and Valeriana D 2 contains.
Ambulant wurden bisher eine größere Anzahl von Patienten mit Psoriasis behandelt, die zum Teil schon jahrzehntelang an dieser Krankheit litten, regelmäßig Rezidive aufwiesen und entweder zahlreiche Cortisonbehandlungen mit ent sprechenden Nebenwirkungen hinter sich hatten oder zum Teil von ihren Hautärzten als therapieresistent angesehen wurden. Die Patienten erhielten täglich eine Injektion oder nahmen das Medikament per oral in ent sprechender Dosierung. Bei einigen Patienten, die an fänglich auf die Therapie verzögert ansprachen, wurden zusätzlich Eigenblut-Injektionen von täglich 4-5 ml verabreicht. Unterstützend wurde allen Patienten empfohlen, eine ballaststoffreiche Diät unter Verzicht auf stark säurehaltige Lebensmittel einzuhalten. So far, a large number of patients have been outpatient treated with psoriasis, some of which have been around for decades suffered from this disease, had regular recurrences and either numerous cortisone treatments with ent talking side effects or partly by their dermatologists as therapy-resistant were viewed. The patients received one every day Injection or ingested the drug orally speaking dosage. In some patients who have response to therapy was delayed additional blood injections of 4-5 ml daily administered. All patients were supported Recommended to avoid a high-fiber diet to adhere to strongly acidic foods.
Bei Patienten, die an starkem Juckreiz litten, war ein Verschwinden oder eine Verringerung des Juckreizes bereits nach kurzer Zeit wie etwa einer Woche fest zustellen. Nach 3-4 Wochen sind großflächige Erytheme in der Regel verblaßt; nach 6 Wochen ist fast bei allen Patienten eine völlige Abheilung der betroffenen Hautstellen festzustellen. Neben wirkungen oder Unverträglichkeitserscheinungen wurden bisher in keinem einzigen Fall berichtet.Patients with severe itching experienced a disappearance or a reduction in the itching after a short time, such as a week. After 3-4 weeks, large-scale erythema is usually faded; after 6 weeks, almost all patients showed a complete healing of the affected skin. In addition to effects or symptoms of intolerance, no case has been reported so far.
Keiner der behandelten Patienten hatte bisher ein Rezidiv; der längste Beobachtungszeitraum beträgt bisher 4 Jahre.None of the patients treated had one Recurrence; is the longest observation period 4 years so far.
Ein 2jähriges Mädchen, das seit seinem 6. Lebensmonat an einer schweren Neurodermatitis litt, wurde mit dem erfindungsgemäßen Mittel behandelt. Das Kind wurde von den bisher behandelnden Hautärzten als therapieresistent angesehen und ihr mußten beim Schlafen Hände und Füße festgebunden werden, um das ständige Kratzen wegen des starken Juckreizes zu verhindern.A 2 year old girl who has been 6 months old suffered from severe neurodermatitis, with the Treated agents according to the invention. The child was born by the previously treating dermatologists as therapy-resistant looked and you had hands and feet when sleeping be tied to the constant scratching because of the to prevent severe itching.
Nach etwa 10 wöchiger Behandlung war das Kind frei von Juckreiz; die Hauterscheinungen hatten sich stark ab geschwächt. Nach einer weiteren 10 wöchigen Behandlungs dauer waren sämtliche Hauterscheinungen restlos ver schwunden, die Haut hatte sich vollständig regeneriert und war glatt und weich. Ein Rezidiv ist in der bisherigen fast einjährigen Beobachtungszeit nicht festgestellt worden.After about 10 weeks of treatment, the child was free from Itching; the skin symptoms had abated weakened. After another 10 weeks of treatment all skin symptoms were completely gone disappeared, the skin had completely regenerated and was smooth and soft. A recurrence is in the past almost one year of observation was not determined.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19863641220 DE3641220A1 (en) | 1986-12-03 | 1986-12-03 | Pharmaceutical compositions for treatment of psoriasis or neurodermatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19863641220 DE3641220A1 (en) | 1986-12-03 | 1986-12-03 | Pharmaceutical compositions for treatment of psoriasis or neurodermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3641220A1 true DE3641220A1 (en) | 1988-06-16 |
Family
ID=6315318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19863641220 Withdrawn DE3641220A1 (en) | 1986-12-03 | 1986-12-03 | Pharmaceutical compositions for treatment of psoriasis or neurodermatitis |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE3641220A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000029006A1 (en) * | 1998-11-17 | 2000-05-25 | James Giles | Composition for suppressing appetite and for achieving an alert, yet calm state |
| US6280736B1 (en) | 1995-09-29 | 2001-08-28 | Ur. Willmar Schwabe Gmbh & Co, | Stable extract of Hypericum perforatum L.,process for preparing the same and pharmaceutical compositions |
| DE19619512C5 (en) * | 1995-09-29 | 2006-04-20 | Dr. Willmar Schwabe Gmbh & Co. Kg | Stable extract of Hypericum perforatum L., process for its preparation and pharmaceutical preparations |
| DE102007044916A1 (en) | 2007-09-19 | 2009-04-23 | Bionorica Ag | Cosmetic or dermatological composition for topical use |
| WO2010045969A1 (en) * | 2008-10-21 | 2010-04-29 | Naturveda | New synergic association for the treatment of deep skin or mucosa injuries |
-
1986
- 1986-12-03 DE DE19863641220 patent/DE3641220A1/en not_active Withdrawn
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6280736B1 (en) | 1995-09-29 | 2001-08-28 | Ur. Willmar Schwabe Gmbh & Co, | Stable extract of Hypericum perforatum L.,process for preparing the same and pharmaceutical compositions |
| DE19619512C5 (en) * | 1995-09-29 | 2006-04-20 | Dr. Willmar Schwabe Gmbh & Co. Kg | Stable extract of Hypericum perforatum L., process for its preparation and pharmaceutical preparations |
| WO2000029006A1 (en) * | 1998-11-17 | 2000-05-25 | James Giles | Composition for suppressing appetite and for achieving an alert, yet calm state |
| DE102007044916A1 (en) | 2007-09-19 | 2009-04-23 | Bionorica Ag | Cosmetic or dermatological composition for topical use |
| WO2010045969A1 (en) * | 2008-10-21 | 2010-04-29 | Naturveda | New synergic association for the treatment of deep skin or mucosa injuries |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69028542T2 (en) | Felbamat used to treat Lennox-Gastaut syndrome | |
| DE3413052A1 (en) | PHARMACEUTICAL PREPARATION AND THE USE THEREOF FOR TREATING SKIN DISEASES | |
| DE3855323T2 (en) | Galenic 2-beta mimetic forms for per- and sublingual administration | |
| DE3705151A1 (en) | WARTS | |
| EP0435913B1 (en) | Effervescent tablet | |
| EP0796103B1 (en) | Use of incense in the treatment of alzheimer's disease | |
| DE2802924A1 (en) | MEDICINAL PRODUCTS FOR TREATING ACNE | |
| DE3603564C2 (en) | Pharmaceutical preparations with analgesic effectiveness based on diclofenac | |
| DE69825279T2 (en) | USE OF GLUCOSAMINE AND GLUCOSAMINE DERIVATIVES FOR THE FAST RELIEF OF JUCKREIZ OR LOCALIZED PAIN | |
| EP0037488B1 (en) | Pharmaceutical composition for healing inflammatory and/or degenerative and/or atrophic mucous membranes | |
| EP0869807B1 (en) | Use of a medicament and use of mixture of substances to produce a medicament | |
| DE2206570C3 (en) | Use of (+) - catechin | |
| DE60009145T2 (en) | COMPOSITION OF GINSENG AND GINKGO TO IMPROVE COGNITIVE ASSETS | |
| DE3641220A1 (en) | Pharmaceutical compositions for treatment of psoriasis or neurodermatitis | |
| US5376372A (en) | Analgesic and inflammation-reducing medicament | |
| WO1998042357A1 (en) | Use of an extract of alchemilli vulgaris | |
| DE19726871C1 (en) | Synergistic compositions for the selective control of tumor tissue | |
| DE2720420A1 (en) | COMBINATION OF ACTIVE INGREDIENTS AGAINST SUNNYTHEM AND MEDICINAL PRODUCT CONTAINING THIS | |
| DE602004007304T2 (en) | Use of N2O for the treatment of postischemic cerebral cell damage | |
| DE69900336T2 (en) | PENTOXIFYLLIN AND ANTIZYTOKIN PHARMACEUTICAL COMPOSITIONS | |
| DE19732323C2 (en) | Drug combination for increased drug concentration in tissues | |
| DE2801867A1 (en) | ANTICOAGULAN MEDICINAL PRODUCTS BASED ON HEPARIN | |
| DE3440140C2 (en) | Use of thiamphenicol to get used to central analgesics | |
| DE69526111T2 (en) | COMPOSITION FOR TREATING ENDOMETRIOSE, WHICH CONTAINS A SALT OF A PRECIOUS METAL AND MEL CUM SALE | |
| DE3511236C2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |